Neuroscience research has been revolutionized by the use of recombinant viral vector technology from the basic, preclinical and clinical levels. Currently, multiple recombinant viral vector types are employed with each having its strengths and weaknesses depending on the proposed application. Helper-dependent adenoviral vectors (HdAd) are emerging as ideal viral vectors that solve a major need in the neuroscience field: (1) expression of transgenes that are too large to be packaged by other viral vectors and (2) rapid onset of transgene expression in the absence of cytotoxicity. Here, we describe the methods for large-scale production of HdAd viral vectors for in vivo use with neurospecific transgene expression.
You may also like
New director for the Ernst Strüngmann Institute
April 6, 2021Ernst Strüngmann Institute for Neuroscience
Hot on the messenger’s trail
March 30, 2021Max Planck Institute for Brain Research
The astonishing self-organization skills of the brain
March 23, 2021Max Planck Institute for Biological Cybernetics
How the brain teaches itself to see
March 16, 2021Max Planck Institute for Brain Research
The fruit fly and its comb-shaped neurons
February 1, 2021Ernst Strüngmann Institute for Neuroscience
Science on film, episode 4: Motivational states of the...
January 29, 2021Max Planck Institute for Biological Cybernetics